How to buy Avadel Pharmaceuticals stock

Avadel Pharmaceuticals plc is a drug manufacturers-specialty & generic business based in the US. Avadel Pharmaceuticals shares (AVDL) are listed on the NASDAQ and all prices are listed in US Dollars. Avadel Pharmaceuticals employs 32 staff and has a trailing 12-month revenue of around 0.00.

Avadel Pharmaceuticals share price

Use our graph to track the performance of AVDL stocks over time.

Avadel Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-04-30.

52-week range	$4.83 - $10.33
50-day moving average	$8.81
200-day moving average	$7.43
Wall St. target price	$18.56
PE ratio	60.3846
Dividend yield	N/A (0%)
Earnings per share (TTM)	$0.13

Buy Avadel Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Avadel Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Avadel Pharmaceuticals plc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Avadel Pharmaceuticals under- or over-valued?

Valuing Avadel Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Avadel Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Avadel Pharmaceuticals's P/E ratio

Avadel Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 60x. In other words, Avadel Pharmaceuticals shares trade at around 60x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Avadel Pharmaceuticals's PEG ratio

Avadel Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.07. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Avadel Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Avadel Pharmaceuticals financials

Revenue TTM	$22.3 million
Gross profit TTM	$16.6 million
Return on assets TTM	-9.9%
Return on equity TTM	10.56%
Profit margin	31.47%
Book value	$2.78
Market capitalisation	$459 million

TTM: trailing 12 months

Shorting Avadel Pharmaceuticals shares

There are currently 4.0 million Avadel Pharmaceuticals shares held short by investors – that's known as Avadel Pharmaceuticals's "short interest". This figure is 1.8% up from 3.9 million last month.

There are a few different ways that this level of interest in shorting Avadel Pharmaceuticals shares can be evaluated.

Avadel Pharmaceuticals's "short interest ratio" (SIR)

Avadel Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Avadel Pharmaceuticals shares currently shorted divided by the average quantity of Avadel Pharmaceuticals shares traded daily (recently around 266841.24331551). Avadel Pharmaceuticals's SIR currently stands at 14.96. In other words for every 100,000 Avadel Pharmaceuticals shares traded daily on the market, roughly 14960 shares are currently held short.

However Avadel Pharmaceuticals's short interest can also be evaluated against the total number of Avadel Pharmaceuticals shares, or, against the total number of tradable Avadel Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Avadel Pharmaceuticals's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Avadel Pharmaceuticals shares in existence, roughly 70 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Avadel Pharmaceuticals shares, roughly 0 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Avadel Pharmaceuticals.

Find out more about how you can short Avadel Pharmaceuticals stock.

Avadel Pharmaceuticals share dividends

We're not expecting Avadel Pharmaceuticals to pay a dividend over the next 12 months.

Avadel Pharmaceuticals share price volatility

Over the last 12 months, Avadel Pharmaceuticals's shares have ranged in value from as little as $4.83 up to $10.325. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Avadel Pharmaceuticals's is 1.4021. This would suggest that Avadel Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Avadel Pharmaceuticals overview

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. The company's lead product candidate is FT218, a formulation of sodium oxybate which is in a Phase 3 clinical trial for the treatment excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland. .

Frequently asked questions

• What percentage of Avadel Pharmaceuticals is owned by insiders or institutions?

  Currently 5.891% of Avadel Pharmaceuticals shares are held by insiders and 57.38% by institutions.

• How many people work for Avadel Pharmaceuticals?

  Latest data suggests 32 work at Avadel Pharmaceuticals.

• When does the fiscal year end for Avadel Pharmaceuticals?

  Avadel Pharmaceuticals's fiscal year ends in December.

• Where is Avadel Pharmaceuticals based?

  Avadel Pharmaceuticals's address is: 10 Earlsfort Terrace, Dublin, Ireland, 2

• What is Avadel Pharmaceuticals's ISIN number?

  Avadel Pharmaceuticals's international securities identification number is: US05337M1045

• What is Avadel Pharmaceuticals's CUSIP number?

  Avadel Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 05337M104